Who's in, who's out in Week 10? Fantasy Football Live gets you ready for this week with the latest injury news.
Who's in, who's out in Week 10? Fantasy Football Live gets you ready for this week with the latest injury news.
AC Hotel Park City, owned by Ensign Hospitality, opens its doors on Dec. 7, 2020, inviting travelers to experience a hotel with style and intention in Utah's cultured city. Part of AC Hotels by Marriott®, the design-driven hotel brand from Marriott International, this newly constructed hotel combines a small-town lodge feel with elegant, comfortable rooms and sleek, modern amenities, bringing purposeful design to Park City.
(Bloomberg) -- Indonesia’s lenders are pushing back against central bank pressure to further lower interest rates for their customers, a step policy makers believe can help pull the economy out of recession.The banks say the real problem is that people don’t want to borrow in the first place. Loans shrank in October for the first time on record, down 0.47% from the year-earlier period. Bank Indonesia Governor Perry Warjiyo said the contraction was due to lenders’ risk-averse attitude and could have been avoided if they had lowered rates for customers in line with central bank easing.“At a time like now, people just aren’t looking to obtain loans because their activities are limited anyway,” said Haru Koesmahargyo, finance director at state-owned PT Bank Rakyat Indonesia, which has the biggest credit portfolio among Indonesian banks at 935.3 trillion rupiah ($66 billion).Banks’ reluctance to cut borrowing costs poses a hurdle for President Joko Widodo’s plan to lift Southeast Asia’s largest economy out of its first recession in more than two decades. People are limiting their spending as unemployment surges to a nine-year high and businesses are delaying investments as the country grapples with Southeast Asia’s worst coronavirus outbreak, at more than 500,000 total cases.While the central bank has cut its key rate by 225 basis points since June 2019 to a record-low 3.75%, PT Bank Central Asia, the largest lender by market value, has eased rates for customers by only about 100 basis points during the same period. Bank Rakyat has cut borrowing costs by 25 to 50 basis points this year, short of the 125 basis points the monetary authority has cut policy rates in 2020.“Why haven’t loan rates declined yet? Because of risk perception by banks,” Warjiyo said at a Nov. 19 monetary policy briefing. The central bank is meeting with lenders and businesses to boost lending, with sectors including food and beverages, telecommunications and basic minerals likely to drive the demand, he said Tuesday.Bank Rakyat shares were among the biggest laggard in Indonesia’s stock benchmark on Thursday, declining 0.9% as of midday break, while the Jakarta Composite Index surged 0.7%. BCA gained 0.2%.Loan RestructuringBanks have reason for being hesitant to lend: Non-performing loans have stayed above 3% since May as individuals and companies struggle to repay debts, which could put pressure on banks’ balance sheets.The Financial Services Authority said it’s only a matter of time until lending rates drop; the main issue holding banks back is ongoing loan restructuring, according to Chairman Wimboh Santoso. More than 932 trillion rupiah of loans had been restructured this year as of Oct. 26, equivalent to about 17% of total borrowing.A few sectors are already showing early signs of recovery, including insurance, chemicals and pharmaceuticals, and the FSA will push for more credit growth from those industries, it said in a statement Thursday.Bank Rakyat is putting loan growth on the back burner to focus on improving the quality of current loans, Koesmahargyo said. It’s targeting loan growth of 4%-5% this year, compared with 8.3% in 2019.“Credit and rates aren’t the key issue now,” according to BCA President Director Jahja Setiaatmadja, who expects the bank’s loans in 2020 to remain the same as 2019. “If we want to boost the economy, just use government subsidies to directly support the industries, instead of relying on loans.”(Updates with FSA statement in 10th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The Bank of Japan is quietly walking back its unpopular negative interest rates policy with a controversial scheme designed to drive mergers among weaker, smaller lenders, a move some insiders see as a risky deviation into industrial reform. As COVID-19 adds pain for regional banks suffering from years of ultra-low interest rates, the BOJ this month unveiled a plan to pay 0.1% interest on deposits held by lenders that cut costs, boost profits or consolidate. The programme means the BOJ will for the first time offer payouts to a specific industry with the aim of driving reform in that sector.
And another thing: People to be thankful for in 2020.
The twins, who were conjoined at the top of their heads, were separated in a historic surgery in 2017.
VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sectors, is pleased to provide an update and overview regarding its expansion into the functional mushroom wellness sector. With interest in functional and medicinal mushrooms climbing sharply, particularly regarding medicinal opportunities, the outlook appears promising for the sector. Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically. As a study candidate psilocybin is being looked at for treatment options including depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction. The U.S. Food and Drug Administration (USFDA) status on the use of psychedelics appears to be evolving, subsequent to breakthrough therapy status for treatment-resistant depression in 2020 which appears poised to receive approvals in 2021. Recent reports also indicate that the global market for functional mushrooms, is forecasted to reach $34.3 billion USD by 2024 and continues growing at a respectable CAGR of 8%.As a result of the encouraging and growing interest in the sector, Pure Extracts has commenced the expansion of its business model to include mushroom formulations through the use of extraction processes that have proven compatible with its existing infrastructure. The Company is working closely with its scientific advisor, Dr. Alexander MacGregor, the founder of the Toronto Institute of Pharmaceutical Technology, to develop high bio-available products and novel delivery methodologies including pills, capsules, and edibles. Furthermore, the Company believes that there exists a significant opportunity for it to become an important extraction partner for the commercialization of new functional mushroom products designed with purity and consistency in mind. In that regard, Pure Extracts has signed a Letter of Intent (LOI) with one of Canada’s leading functional mushroom wellness brands to co-develop CBD enhanced mushroom products.Looking further ahead, Pure Extracts aims to eventually enter the growing field of psychedelic mushroom processing as an additional aspect of its diverse extraction market penetration strategy. In the interim, three functional products such as lion’s mane, turkey tail and reishi are being created under the ‘Pure Mushrooms’ brand. In herbal medicine, these products are thought to boost memory, support the immune system or reduce stress. Pure Mushrooms products are projected for availability by the end of Q1 2021 via direct-to-consumer sales utilizing the Company’s capital efficient, e-Commerce web portal. The creation of these products will validate the Company’s processes and capabilities and prepare it as additional strains become available.Company CEO, Ben Nikolaevsky notes, “Our brand is an aspirational extension of our location in the mountains of British Columbia. As such, we are 100% focused on high quality ingredients, formulations, and processes in all our efforts. Moving into the field of mushroom extractions is an obvious and exciting opportunity to leverage our advanced technology and proven capabilities. We look forward to launching our functional products commercially within the next few months and can’t help but see the similarities to the cannabis sector regarding the pathways to both medical and recreational legalization. I believe our ability to immediately begin working in this burgeoning sector will create immense value for our business, our stakeholders, partners and shareholders alike.”About Pure Extracts (CSE: PULL) (XFRA: A2QJAJ) The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.For further information please contact Empire Communications Group at (604) 343-2724.ON BEHALF OF THE BOARD “Ben Nikolaevsky” Ben Nikolaevsky CEO and DirectorThe CSE has neither approved nor disapproved the contents of this press release.This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.
"Hello, Liza. This is John Mellencamp. What do you want to talk about?" It’s a cold, cloudy East Coast afternoon, and, for so many reasons, including John’s 69th birthday on Oct. 7, it’s been tough for us to connect. "I want to talk about you," I say. "Boy, that's…
Michael Hancock urged residents to stay at home, before admitting he travelled to Mississippi.
Six members of the Pakistan cricket squad in New Zealand have tested positive for COVID-19 and have been moved from managed isolation into quarantine. Two of the cases are deemed historical and four are new but all six players will move to the quarantine arm of their isolation facility. The Pakistan team’s exemption to train while in managed isolation will be withheld until an investigation has been completed.
Concerns over the accessibility of testing or the ability of testing to produce valid results resulted in the decision to push the exams to 2022.
SPIN launched in the peak MTV era, when an innovative — or even just salacious — music video could make or break an artist. Thirty five years later, YouTube is an obligatory part of any promotional push, but no one’s counting on a mind-blowing clip to sell a record. (The views…
Sink into a brand new mattress and save up to 30 percent — then top it off with buttery soft sheets, cozy blankets, luxurious pillows and more for a steal.
Is Starbucks open on Thanksgiving? Yes, select locations are open Thursday. Select Burger King, McDonald's, Del Taco, also are open this Turkey Day.
What grocery stores are open on Thanksgiving 2020? Albertsons, Kroger and Whole Foods are open, but Aldi, Costco, Walmart and Publix are closed.
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN). The class action, filed in United States District Court for the District of New Jersey, and docketed under 20-cv-015228, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Celsion securities between November 2, 2015 and July 10, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are a shareholder who purchased Celsion securities during the class period, you have until December 28, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at email@example.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action]Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.In February 2014, Celsion announced that the U.S. Food and Drug Administration (“FDA”) had reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation (“RFA”) in primary liver cancer, also known as hepatocellular carcinoma (“HCC”), called the “OPTIMA Study.” The trial design was purportedly based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival (“OS”) in a substantial number of HCC patients that received an optimized RFA treatment.The OPTIMA Study was expected to enroll 550 patients globally, with up to 100 sites in the U.S., Europe, China and Asia Pacific, to evaluate ThermoDox in combination with RFA. The primary endpoint for the trial was OS, and the statistical plan called for two interim efficacy analyses by an independent Data Monitoring Committee (“DMC”).The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had significantly overstated the efficacy of ThermoDox; (ii) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.On July 13, 2020, Celsion announced that “it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer.” According to the Company, “[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020,” which “found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903.”On this news, Celsion’s stock price fell $2.29 per share, or 63.97%, to close at $1.29 per share on July 13, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980. The investigation concerns whether Boston Scientific and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On November 17, 2020, Boston Scientific announced a global recall of all unused inventory of the Company’s LOTUS Edge Aortic Valve System, citing “complexities associated with the product delivery system.” Boston Scientific further announced that “[g]iven the additional time and investment required to develop and reintroduce an enhanced delivery system, the company has chosen to retire the entire LOTUS product platform immediately.” On this news, Boston Scientific’s stock price fell $3.00 per share, or 7.89%, to close at $35.03 per share on November 17, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HP Inc. (“HP” or the “Company”) (NYSE: HPQ). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980. The investigation concerns whether HP and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On June 21, 2016, HP announced an overhaul to its Printing sales model and revealed that it would reduce the Supplies channel inventory by $450 million in Supplies revenue over the remainder of 2016. On this news, HP’s stock price fell $0.72 per share, or 5.4%, to close at $12.61 per share on June 22, 2016. More than four years later, on September 30, 2020, the U.S. Securities and Exchange Commission (“SEC”) issued a press release, announcing charges against HP “for misleading investors by failing to disclose the impact of sales practices undertaken to meet quarterly sales and earnings targets.” Specifically, the SEC stated that “from early 2015 through the middle of 2016, in an effort to meet quarterly sales targets, regional managers at HP used a variety of incentives to accelerate, or ‘pull-in’ to the current quarter, sales of printing supplies that they otherwise expected to materialize in later quarters.” The press release further stated that “HP has agreed to pay $6 million to settle the charges.” The SEC’s charges against HP revealed that while the Company’s June 21, 2016 announcement had attributed its channel inventory issues and revenue and margin reductions to unfavorable currency impacts, competitive pricing pressure, and a change in inventory modeling, HP had in reality engaged in improper channel inventory management and sales practices.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
As part of our 35th anniversary, we’re naming the most influential artists of the past 35 years. Today, we’re at 11. From Los Angeles, California, here are the Guns N' Roses. Bursting out of the Sunset Strip faster than you can say "Welcome to the Jungle," Guns N’ Roses became both…
Detroit Lions running back Adrian Peterson is ban